Motus GI (MOTS) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Motus GI in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MOTS shares.
View MOTS analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1 year price targets for Motus GI's shares. Their MOTS share price forecasts range from $2.25 to $10.00. On average, they predict the company's share price to reach $5.81 in the next year. This suggests a possible upside of 780.7% from the stock's current price.
View analysts price targets for MOTS or view top-rated stocks among Wall Street analysts.

Motus GI's stock was trading at $0.84 at the beginning of the year. Since then, MOTS shares have decreased by 21.4% and is now trading at $0.66.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our MOTS earnings forecast.

Motus GI Holdings, Inc. (NASDAQ:MOTS) issued its quarterly earnings data on Friday, November, 12th. The company reported ($2.00) EPS for the quarter, meeting the consensus estimate of ($2.00). The company earned $0.14 million during the quarter, compared to the consensus estimate of $0.12 million. Motus GI had a negative net margin of 2,893.79% and a negative trailing twelve-month return on equity of 1,018.59%. During the same quarter in the prior year, the firm posted ($2.60) earnings per share.

Motus GI shares reverse split on the morning of Tuesday, July 26th 2022. The 1-20 reverse split was announced on Tuesday, July 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Motus GI investors own include Matinas BioPharma (MTNB), Allena Pharmaceuticals (ALNA), VYNE Therapeutics (VYNE), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Pfizer (PFE), Gilead Sciences (GILD) and Marinus Pharmaceuticals (MRNS).

(MOTS) raised $21 million in an initial public offering on Wednesday, February 14th 2018. The company issued 3,500,000 shares at a price of $5.00-$7.00 per share. Piper Jaffray served as the underwriter for the IPO and Oppenheimer & Co. was co-manager.

Motus GI trades on the NASDAQ under the ticker symbol "MOTS."

Shares of MOTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MOTS stock can currently be purchased for approximately $0.66.

Motus GI (NASDAQ:MOTS) has a market capitalization of $3.15 million and generates $590,000.00 in revenue each year. The company earns $-18,600,000.00 in net income (profit) each year or ($5.26) on an earnings per share basis.

Motus GI's mailing address is 1301 EAST BROWARD BOULEVARD 3rd Floor, FT. LAUDERDALE FL, 33301. The official website for the company is www.motusgi.com. The company can be reached via phone at (954) 541-8000, via email at ir@motusgi.com, or via fax at 954-541-8265.